STEM CELL TREATMENT FOR CENTRAL NERVOUS SYSTEM DISEASES

Initial £16,000 January

This business has recently received $3.8m investment from a respected strategic pharma industry insider. A further £1.5m on the same terms and now being sought will enable the company to advance its product into human trials for the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease). The client has protected IP covering purification of its adult stem cell product and its use in numerous diseases of the brain and spine requiring repair of damaged nerves. As the product and repair process is entirely natural occurrence in the body, regulatory authorities indicate low concern about potential safety issues. Investors will hold publicly listed shares and can expect an exit upon conclusion of Phase I/II clinical studies at increased valuations. A major licensee or company acquisition is expected to emerge at that stage. Favourable price inflections are expected at the: filing of IND; reporting of study results, and announcement of license or acquisition.

Acting for Beer & Partners Ltd – Simon Heywood & Richard Silberbauer – London Region